Cost Minimization Analysis of Intravenous or Subcutaneous Trastuzumab Treatment in Patients With HER2-Positive Breast Cancer in Ireland

Trastuzumab/Hyaluronidase-oysk: A New Option for Patients With HER2-Positive Breast Cancer

“…Although it is difficult to extrapolate costs from countries outside of the United States in both the international studies mentioned, the indirect cost of IV trastuzumab exceeds that of trastuzumab/hyaluronidase-oysk over a 52-week period. 22,24 Although there was no statistical significance demonstrated, SQ trastuzumab has a smaller burden on both health care practitioner cost per patient and time per patient; similarly, there is a significantly decreased chair time per patient for trastuzumab/ hyaluronidase-oysk. See Table 3 for details regarding the monetary, staffing, and resource differences between the 2 formulations.…”

“…4 IV trastuzumab involves additional dose calculations based on weight, use of loading doses, aseptic compounding, infusions over 30 to 90 minutes, central line placement (in select patients), IV bag preparation, and increased duration of chair time and nursing resources compared with the SQ formulation. [20][21][22][23][24][25] A study of 48 patients from 2 university hospitals in Ireland described that the overall health care team spends 79% less time per patient receiving the SQ formulation as opposed to the IV formulation of trastuzumab. 22 A study of 70 patients from 18 hospital sites in Canada noted that chair time per trastuzumab/ hyaluronidase-oysk patient is 55 to 57 minutes shorter in duration than that for IV trastuzumab, and health care practitioner time is 13 to 17 minutes shorter in the same regard.…”

“…[20][21][22][23][24][25] A study of 48 patients from 2 university hospitals in Ireland described that the overall health care team spends 79% less time per patient receiving the SQ formulation as opposed to the IV formulation of trastuzumab. 22 A study of 70 patients from 18 hospital sites in Canada noted that chair time per trastuzumab/ hyaluronidase-oysk patient is 55 to 57 minutes shorter in duration than that for IV trastuzumab, and health care practitioner time is 13 to 17 minutes shorter in the same regard. 23 Direct cost differences between the SQ and IV formulations of trastuzumab are comparable.…”

“…25 In the other studies discussed above, patients preferred the SQ formulation over the IV formulation because of tolerability, convenience, dosing frequency, and ease of administration. 8,[20][21][22][23][24][25][26]…”

A cost comparison study to review community versus acute hospital models of nursing care delivered to oncology patients

“…No discounting was needed given that the data collection period was carried out over 3 months. Similar methods of time-related cost calculation have been used by the study team previously (O'Brien et al, 2018(O'Brien et al, , 2019.…”